Cookie Settings

We use cookies to optimize our website. These include cookies that are necessary for the operation of the site, as well as those that are only used for anonymous statistic. You can decide for yourself which categories you want to allow. Further information can be found in our data privacy protection .


These cookies are necessary to run the core functionalities of this website and cannot be disabled.

Name Webedition CMS
Purpose This cookie is required by the CMS (Content Management System) Webedition for the system to function correctly. Typically, this cookie is deleted when the browser is closed.
Name econda
Purpose Session cookie emos_jcsid for the web analysis software econda. This runs in the “anonymized measurement” mode. There is no personal reference. As soon as the user leaves the site, tracking is ended and all data in the browser are automatically deleted.

These cookies help us understand how visitors interact with our website by collecting and analyzing information anonymously. Depending on the tool, one or more cookies are set by the provider.

Name econda
Purpose Statistics
External media

Content from external media platforms is blocked by default. If cookies from external media are accepted, access to this content no longer requires manual consent.

Name YouTube
Purpose Show YouTube content
Name Twitter
Purpose activate Twitter Feeds

CRISPR RNA-guided FokI nucleases repair a disease-causing variant in the PAH gene in a phenylketonuria model

Scheme of the process: one dimer of the FokI-dCas9 complex binds to two “half-sites” on the genome with a certain spacer length and generate double-strand breaks in the DNA. The double-strand breaks are then repaired by homology directed repair, introducing the non-mutated sequence provided as an oligonucleotide.

In a proof-of-concept study, we demonstrated the potential of an improved CRISPR/Cas9 system  the FokI-dCas9 system  for precision medicine, in particular for targeting phenylketonuria (PKU) and other monogenic metabolic diseases. The FokI-dCas9 system can greatly improve the specificity of genome editingIn contrast to the standard system, it requires dimerization of the FokI-dCas9-sgRNA complex, meaning that monomeric FokI-dCas9-sgRNA is unable to cut the DNA strand, thus reducing substantially the chances of contaminating off-target effects.

PKU is the most common inherited disease in amino acid metabolism. It leads to severe neurological and neuropsychological symptoms if untreated or late diagnosed. Correction of the disease-causing variants in the phenylalanine hydroxylase (PAH) gene could rescue residual activity and restore normal function. The CRISPR/Cas9 system is a recently developed genome editing technique. We applied a modification, which employs the fusion of inactive Cas9 (dCas9) and the FokI endonuclease (FokI-dCas9) to correct the most common variant (allele frequency 21.4%) in the PAH gene - c.1222C>T (p.Arg408Trp) - as an approach toward curing PKU. Co-expression of a single guide RNA plasmid, a FokI-dCas9-zsGreen1 plasmid, and the presence of a single-stranded oligodeoxynucleotide in PAH_c.1222C>T COS-7 cells – an in vitro model of PKU – corrected the PAH variant and restored PAH activity.


Pan et al. (2016) Sci. Rep. 6, 35794. [PDF]

to top
powered by webEdition CMS